相似文献
1
Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia.
Mediators Inflamm. 2020 Oct 28;2020:7958316. doi: 10.1155/2020/7958316. eCollection 2020.
2
Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
Differentiation. 2013 Apr-Jun;85(4-5):140-9. doi: 10.1016/j.diff.2013.02.006. Epub 2013 Jun 20.
3
Endocrine control of benign prostatic hyperplasia.
Andrology. 2016 May;4(3):404-11. doi: 10.1111/andr.12186. Epub 2016 Apr 18.
4
Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
J Clin Endocrinol Metab. 2001 Apr;86(4):1700-6. doi: 10.1210/jcem.86.4.7413.
5
Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
J Steroid Biochem. 1983 Jul;19(1A):155-61.
6
Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
Differentiation. 2011 Nov-Dec;82(4-5):184-99. doi: 10.1016/j.diff.2011.04.006. Epub 2011 May 26.
7
Combined treatment with dihydrotestosterone and lipopolysaccharide modulates prostate homeostasis by upregulating TNF-α from M1 macrophages and promotes proliferation of prostate stromal cells.
Asian J Androl. 2022 Sep-Oct;24(5):513-520. doi: 10.4103/aja2021114.
8
Endogenous androgen levels in epithelium and stroma of human benign prostatic hyperplasia and normal prostate.
Acta Endocrinol (Copenh). 1982 Aug;100(4):634-40. doi: 10.1530/acta.0.1000634.
9
[Histological changes of the prostate and acute urinary retention in patients with benign prostatic hyperplasia].
Zhonghua Nan Ke Xue. 2013 Sep;19(9):811-4.
10
Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.
Prostate. 2020 Jul;80(10):731-741. doi: 10.1002/pros.23986. Epub 2020 May 1.
引用本文的文献
1
The pathogenesis of benign prostatic hyperplasia and the roles of Prdx3, oxidative stress, pyroptosis and autophagy:a review.
Front Oncol. 2025 Aug 5;15:1579539. doi: 10.3389/fonc.2025.1579539. eCollection 2025.
2
Green chemistry for prostate health: exploring nature's toolbox against cancer, inflammation, and hyperplasia.
Mol Divers. 2025 Aug 5. doi: 10.1007/s11030-025-11305-4.
3
Stigmasterol as a ptotential phytotherapeutic agent for benign prostatic hyperplasia: modulation of inflammation, oxidative stress, and apoptosis.
Mol Biol Rep. 2025 Jul 21;52(1):740. doi: 10.1007/s11033-025-10847-y.
4
Effect of Fenugreek Extract on Testosterone Propionate-Induced Benign Prostatic Hyperplasia.
Int J Mol Sci. 2025 Jan 31;26(3):1261. doi: 10.3390/ijms26031261.
5
Purple corn extract improves benign prostatic hyperplasia by inhibiting 5 alpha-reductase type 2 and inflammation in testosterone propionate-induced rats.
Front Pharmacol. 2025 Jan 3;15:1485072. doi: 10.3389/fphar.2024.1485072. eCollection 2024.
6
Effect of Proanthocyanidins from Grape Seed Extract on Benign Prostatic Hyperplasia.
Nutrients. 2024 Dec 28;17(1):73. doi: 10.3390/nu17010073.
7
Age-related changes in the impact of metabolic syndrome on prostate volume: a cross-sectional study.
Asian J Androl. 2025 Jul 1;27(4):475-481. doi: 10.4103/aja2024101. Epub 2025 Jan 7.
8
A genetic study to identify pathogenic mechanisms and drug targets for benign prostatic hyperplasia: a multi-omics Mendelian randomization study.
Sci Rep. 2024 Oct 4;14(1):23120. doi: 10.1038/s41598-024-73466-w.
9
Mechanisms and Efficacy of Chinese Herbal Medicines in Benign Prostatic Hyperplasia.
Chin J Integr Med. 2025 Jan;31(1):73-82. doi: 10.1007/s11655-024-3916-0. Epub 2024 Aug 27.
10
Zhuangyao Jianshen pill ameliorates testosterone-induced benign postatic hyperplasia in rats.
J Tradit Chin Med. 2024 Aug;44(4):694-702. doi: 10.19852/j.cnki.jtcm.20240627.001.
本文引用的文献
1
Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia.
World J Urol. 2020 Nov;38(11):2771-2779. doi: 10.1007/s00345-020-03106-1. Epub 2020 Feb 14.
2
A phytosterol-enriched saw palmetto supercritical CO extract ameliorates testosterone-induced benign prostatic hyperplasia by regulating the inflammatory and apoptotic proteins in a rat model.
BMC Complement Altern Med. 2019 Oct 17;19(1):270. doi: 10.1186/s12906-019-2697-z.
3
The angiotensin converting enzyme inhibitor captopril attenuates testosterone-induced benign prostatic hyperplasia in rats; a mechanistic approach.
Eur J Pharmacol. 2019 Dec 15;865:172729. doi: 10.1016/j.ejphar.2019.172729. Epub 2019 Oct 9.
4
Trends in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, 2004 to 2013: the Urologic Diseases in America Project.
J Urol. 2020 Jan;203(1):171-178. doi: 10.1097/JU.0000000000000499. Epub 2019 Aug 20.
5
Guideline of guidelines: testosterone therapy for testosterone deficiency.
BJU Int. 2019 Nov;124(5):722-729. doi: 10.1111/bju.14899. Epub 2019 Sep 11.
6
Prostatic stromal inflammation is associated with bladder outlet obstruction in patients with benign prostatic hyperplasia.
Prostate. 2018 Jul;78(10):743-752. doi: 10.1002/pros.23518. Epub 2018 Apr 2.
7
Finasteride accelerates prostate wound healing after thulium laser resection through DHT and AR signalling.
Cell Prolif. 2018 Jun;51(3):e12415. doi: 10.1111/cpr.12415. Epub 2017 Nov 30.
8
The Response of Prostate Smooth Muscle Cells to Testosterone Is Determined by the Subcellular Distribution of the Androgen Receptor.
Endocrinology. 2018 Feb 1;159(2):945-956. doi: 10.1210/en.2017-00718.
9
Relationships between Circulating and Intraprostatic Sex Steroid Hormone Concentrations.
Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1660-1666. doi: 10.1158/1055-9965.EPI-17-0215. Epub 2017 Aug 22.
10
Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume.
Prostate. 2017 Jul;77(10):1082-1092. doi: 10.1002/pros.23365. Epub 2017 Jun 8.
Zotero 插件